National Prescribing Indicator Biosimilars National Prescribing Indicator

Introduction A biosimilar medicine is: - “a biological medicine that is developed to be highly similar and clinically equivalent to an existing biological medicine”. Biosimilar medicines are different to generic medicines because? Biological medicines including all biosimilars must be prescribed by brand name (MHRA) to support Pharmacovigilance mhra.gov.uk/yellowcard

Introduction A biosimilar medicine is: - “a biological medicine that is developed to be highly similar and clinically equivalent to an existing biological medicine”. Biosimilar medicines are different to generic medicines because? Biological medicines including all biosimilars must be prescribed by brand name (MHRA) to support Pharmacovigilance mhra.gov.uk/yellowcard

Biosimilar work streams National Prescribing Indicators Biosimilar dashboard (cost efficiency work)

National Prescribing Indicators

National Prescribing Indicator process

Biologics spending 2015-2016

Biologics spending 2015-2016

Biosimilar National Prescribing Indicator Why have an National prescribing indicator looking at biosimilars? Continuing development of biological medicines, including biosimilar medicines, creates: - - increased choice for patients and clinicians - increased commercial competition - possible enhanced value propositions for individual medicines - support the treatment of an increasing number of patients and the uptake of new and innovative medicines

Biosimilar National Prescribing Indicator Why have an National prescribing indicator looking at biosimilars? Continuing development of biological medicines, including biosimilar medicines, creates: - - increased choice for patients and clinicians - increased commercial competition - possible enhanced value propositions for individual medicines - support the treatment of an increasing number of patients and the uptake of new and innovative medicines

Biosimilar National Prescribing Indicator – the history First introduced in 2016-2017   Unit of measure: Quantity of biosimilar medicines prescribed as a percentage of total ‘reference’ product plus biosimilar. Target: Increase the appropriate use of cost-effective biological medicines, including biosimilar medicines. Evolving biological medicine basket

Quarter 2 2018-2019 Biosimilar percentages of total biologics across health boards/trust in Wales

Infliximab

Etanercept

Rituximab (intravenous)

Infliximab 94.2%

Etanercept 83.8%

Rituximab (intravenous) 96.3%

NHS England Infliximab Etanercept Rituximab % uptake NHS/Foundation Trusts ranked from lowest to highest Etanercept % uptake NHS/Foundation Trusts ranked from lowest to highest Rituximab % uptake NHS/Foundation Trusts ranked from lowest to highest

Infliximab biosimilar use as a percentage of total infliximab use NHS Scotland Infliximab biosimilar use as a percentage of total infliximab use January to March 2018

Etanercept biosimilar use as a percentage of total etanercept use NHS Scotland Etanercept biosimilar use as a percentage of total etanercept use January to March 2018

Rituximab biosimilar use as a percentage of total rituximab use NHS Scotland Rituximab biosimilar use as a percentage of total rituximab use January to March 2018

Total biosimilar usage (Infliximab, etanercept and rituximab combined) 87%

www.awttc.org

Thank you! Further information NPIs – www.awmsg.org > Medicines Management > National Prescribing Indicators Biosimilar data – www.awttc.org > WAPSU resources > SPIRA > Biosimilar Efficiencies Enquiries – awttc@wales.nhs.uk